Pipeline
Shattuck Labs is advancing a pipeline of novel biologic therapies designed to block the TL1A/DR3 pathway, a key driver of inflammation and immune dysregulation. Our lead program, SL-325, is a first-in-class DR3 blocking antibody engineered for exceptional potency, selectivity, and safety through a Fc-silenced antibody design. Additional preclinical programs, including SL-425 and bispecific DR3 blocking antibodies, aim to expand therapeutic potential across autoimmune and inflammatory diseases.
Shattuck’s Pipeline Targets the TL1A/DR3 Pathway
Shattuck's lead DR3 blocking antibody, SL-325, demonstrates superior potency in preclinical assays compared to antibodies targeting TL1A. SL-325 harnesses the power of high affinity, epitope specificity, and critical Fc-silencing to block TL1A from engaging DR3 expressed on multiple immune cells that drive inflammation.